



POLISH HEART JOURNAL

Kardiologia Polska

The Official Peer-reviewed Journal
of the Polish Cardiac Society
since 1957

Online first

This is a provisional PDF only. Copyedited and fully
formatted version will be made available soon

ISSN 0022-9032

e-ISSN 1897-4279

First-in-Poland thoracoscopic left atrial appendage closure using Novel AtriClip® PRO-V device in patient with previous heart surgery and LAA thrombus

Authors: Mariusz Kowalewski, Natalia Ogorzelec, Sebastian Stec, Piotr Suwalski

Article type: Clinical vignette

Received: September 26, 2024

Accepted: October 29, 2024

Early publication date: November 12, 2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

First-in-Poland thoracoscopic left atrial appendage closure using Novel AtriClip® PRO-V device in patient with previous heart surgery and LAA thrombus

Mariusz Kowalewski^{1, 2, 3}, Natalia Ogorzelec¹, Sebastian Stec^{1, 4}, Piotr Suwalski¹

¹Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warszawa, Poland

²Thoracic Research Centre, Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland

³Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands

⁴Division of Electrophysiology, Cardioneuroablation, Catheter Ablation and Cardiac Stimulation, Subcarpathian Center for Cardiovascular Intervention, Sanok, Poland

Correspondence to:

Mariusz Kowalewski, MD, PhD,

Department of Cardiac Surgery and Transplantology,

National Medical Institute of the Ministry of Interior and Administration,

Wołoska 137, 02–507 Warszawa, Poland,

phone: +48 47 722 12 60,

e-mail: kowalewskimariusz@gazeta.pl

The cornerstone treatment for atrial fibrillation (AF) is based on the prevention of cardioembolism and related stroke with the use oral anticoagulants [1, 2], which inherently increase the risk of bleeding. An additional protection from stroke and a valid alternative for patients at high risk of bleeding and/or intolerant of oral anticoagulants corresponds to left atrial appendage (LAA) exclusion/closure. This can be achieved percutaneously or by surgical techniques such as epicardial AtriClip [3, 4].

Forty-five year old male with history of persistent AF and thoracoscopic AF substrate ablation 20 years before; now with tachycardia induced cardiomyopathy (ejection fraction 20%) was admitted to the Department for LAA exclusion; earlier he underwent pulmonary vein isolation ablation in referring center but the procedure was aborted because of LAA thrombus. He underwent thoracoscopic LAA exclusion procedure. **Figure 1** illustrates the surgical

approach. In brief, the surgery is performed under general anesthesia, with double lumen tube intubation and selective lung ventilation. Transesophageal echocardiography was performed intraoperatively, LAA thrombus presence was confirmed. Left-sided thoracoscopy was followed by pericardial adhesions removal and LAA mobilization for secure and safe clip placement; device deployment is further assessed in transesophageal echocardiography. Chest tube is left in the thorax for 2 days. Patient was discharged uneventfully on post-op day 4th and referred again for the pulmonary vein isolation procedure.

The current experience is the first in Poland use of the novel thoracoscopic AtriClip® PRO-V (AtriCure, Mason, OH, US) device for the LAA exclusion. This is also the first in Europe use of the PRO-V clip in patient with LAA thrombus. The system differs from the previous generations in a way that there is no frame supporting the clip; therefore, all the maneuvers that could potentially injure the LA roof or pulmonary artery when the frame is retracted are avoided. This is particularly important in re-do cases such as this one, as pericardial adhesions limit the movements and access to the LAA. Left atrial appendage thrombus represents a valid contraindication for the LAAO of any kind and AtriClip® placement is off-label use. For the thrombi located far from the LAA ostium, however, (e.g. body or apex), the risk of thrombus migration is minimal. Indeed, with AtriClip® device, the thrombus is entrapped inside the LAA with minimal to none LAA maneuvers. The results of the ongoing Stand-Alone Left Atrial appendage occlusion for thromboembolism prevention in Nonvalvular Atrial Fibrillation Disease Registry (SALAMANDER) [5] will compare the thromboembolic events following LAAO with different devices.

Article information

Conflict of interest: PS serves as consultant for AtriCure. Other authors declared no conflicts of interest.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at polishheartjournal@ptkardio.pl

REFERENCES:

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991; 22(8): 983–988, doi: 10.1161/01.str.22.8.983, indexed in Pubmed: 1866765.
2. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2024; 45(36): 3314–3414, doi: 10.1093/eurheartj/ehae176.PMID:, indexed in Pubmed: 39210723.
3. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke*. 2021; 52(7): e364–e467, doi: 10.1161/STR.0000000000000375, indexed in Pubmed: 34024117.
4. Perreault S, de Denus S, White-Guay B, et al. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. *Pharmacotherapy*. 2020; 40(1): 40–54, doi: 10.1002/phar.2350, indexed in Pubmed: 31758592.
5. Kowalewski M, Wańha W, Litwinowicz R, et al. Stand-Alone left atrial appendage occlusion for thromboembolism prevention in nonvalvular atrial fibrillation disease registry (SALAMANDER): protocol for a prospective observational nationwide study. *BMJ Open*. 2022; 12(9): e063990, doi: 10.1136/bmjopen-2022-063990, indexed in Pubmed: 36130748.




Figure 1. Intra-operative transesophageal echocardiography (A) white arrow points to the dense thrombus in the left atrial appendage (LAA); thoracoscopic adhesions removal and LAA visualization; pericardial traction sutures in place (B). LAA fully mobilized (C). AtriClip® PRO-V thoracoscopic device (D). PRO-V clip placement (E). Echo shows acceptable closure of the LAA (F)